Management Team

  • D. Bruce Modesitt – President & Chief Executive Officer
    Mr. Modesitt is a recognized leader in the femoral artery access and closure field, having been the primary inventor and designer of the Perclose Closer Device. In August 2004, Bruce incorporated Arstasis and transferred into it intellectual property rights for the self-sealing arteriotomy procedure he invented. From November 2011 to present Bruce has served as CTO of Arstasis. From August 2004 through November 2011, he recruited key employees, consultants, suppliers, directors, and investors for Arstasis, and managed the company to commercialization as its President and CEO.From 2003 to 2005, Bruce worked as an independent consultant to medical device manufacturers. From 2000 through 2003, he worked at Fogarty Research & Development where, working with Dr. Fogarty, he developed medical devices for vein harvesting, vein stripping, side branch management, remote endarterectomy, abdominal aortic aneurysm repair, thoracic aortic aneurysm repair and percutaneous heart valve repair. From 1997 through 2000, Bruce worked at Perclose, where he invented the Closer, which caused Abbott Labs to acquire Perclose for $680 million in 1998. From 1995 through 1997, he worked as an engineer at Progressive Angioplasty Systems (PAS). At PAS, Bruce was the primary inventor and designer of the Paragon™ coronary stent. PAS was sold to US Surgical in August of 1997 for $150 million, primarily because of the Paragon stent. The Paragon stent design remains the basis of many stents on the market today. Bruce holds over thirty US patents in the medical device field.

    Bruce was awarded a B.S.M.E. degree from Arizona State University in 1982.

  • Joe Paraschac – Vice President, Research and Development
    Mr. Joe Paraschac joined Arstasis as employee number three in 2006, to create the prototypes Arstasis used to attract investors. Prior to Arstasis, Joe took a leadership role in R&D at Perclose developing their current family of suture mediated closure devices. For this work his team earned the Abbott Laboratories 2002 Hospital Products Division President’s Award. Joe currently holds over 25 medical device patents in the US, and continues to bring over 20 years of experience to the medical device research and development arena.Joe started his career in R&D at Ethicon Endo-Surgery, working with doctors, patent attorneys and marketing strategists to explore a wide variety of instruments for laparoscopic surgical procedures. In a career focused on medical device design and development, Joe has also worked in the ophthalmic industry and developed implants, instruments, and procedures for corrective eye surgery at Keravision, and sleep apnea treatment at Apneon.

    Joe earned an M.S. in Mechanical Engineering from Worcester Polytechnic Institute.

  • Jeremy Wright – Vice President, Sales
    Jeremy Wright joined Arstasis in November 2010 and brings over 15 years of sales and management experience to the Company’s leadership team. His roles in the medical device industry have focused primarily on the peripheral vascular market segment, and have allowed him to develop a comprehensive knowledge of transcatheter and endovascular procedures, specifically the importance of access and closure techniques. Since joining Arstasis, Jeremy has played a pivotal role in developing the market awareness for the Company’s revolutionary femoral access procedure.Prior to joining Arstasis, Jeremy was a part of the senior sales team at Flowcardia, acquired by Bard Peripheral Vascular, where he was responsible for the market penetration of a novel chronic total occlusion catheter. Post-acquisition, he served as a member of the Bard transition team, where his responsibilities included training and leading a team of Bard territory sales managers in their adoption of the Flowcardia family of products. Previously, Jeremy was a territory manager for Edwards Lifesciences, also acquired by Bard Peripheral Vascular, where he was tasked to create markets for the Edwards Lifesciences portfolio of peripheral vascular products. As with Flowcardia, after the sale to Bard, Jeremy was selected as a member of the transition team due to his consistent sales performance and leadership. Other sales positions include tenures with Atrium Medical and Cintas Corporation. Before transitioning into medical device industry sales, Jeremy spent two years as an investment executive with Stifel.

    Jeremy holds a Bachelor of General Studies in Business Communications from The University of Kansas.